Home › Funds › Octagon Capital Advisors LP › TSHA

Octagon Capital Advisors LP position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

Octagon Capital Advisors LP reported holding 9,693,244 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q3 2026 13F filing — a position valued at US$47.2M, representing 6.29% of its reported portfolio and ranking #6 among its reported holdings. Octagon Capital Advisors LP has disclosed TSHA holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)9.69M sh
Reported value held$47.21M
Portfolio Weight6.29%
First reportedQ3 2023
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's TSHA position evolved

Octagon Capital Advisors LP first disclosed a stake in TSHA in Q3 2023 at 2,777,778 shares (US$8.8M). The position peaked in Q2 2026 at 9,693,244 shares, worth US$66.0M. Across 12 filings, Octagon Capital Advisors LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 9,693,244 shares valued at US$47.2M. Notable position changes include a 51% increase in Q2 2024 (shares fell 10% over the following quarter), a 129% increase in Q4 2024 (shares fell 20% over the following quarter), a 28% trim in Q3 2025 (shares rose 68% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.78M $8.78M New
Q1 2024 3.03M $8.70M New
Q2 2024 4.57M $10.24M Add
Q3 2024 4.57M $9.19M Hold
Q4 2024 10.45M $18.08M Add
Q1 2025 10.70M $14.87M Add
Q2 2025 12.59M $29.09M Add
Q3 2025 9.07M $29.65M Reduce
Q4 2025 8.86M $48.73M Reduce
Q1 2026 8.86M $39.60M Hold
Q2 2026 9.69M $66.01M Add
Q3 2026 9.69M $47.21M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 46 other funds we track also report a position in TSHA — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$148.2M), Avoro Capital Advisors LLC (US$116.3M), Vestal Point Capital, LP (US$87.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has Octagon Capital Advisors LP held TSHA?

Octagon Capital Advisors LP has disclosed TSHA holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is Octagon Capital Advisors LP's current position in TSHA?

As of Q3 2026, Octagon Capital Advisors LP holds 9.69M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $47.21M, representing 6.29% of its reported portfolio and ranking #6.

Has Octagon Capital Advisors LP been buying or selling TSHA?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in TSHA. The position peaked in Q2 2026 at 9.69M shares.

Which other funds hold TSHA?

Other major institutional holders of TSHA include RA CAPITAL MANAGEMENT, L.P., Avoro Capital Advisors LLC, Vestal Point Capital, LP, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.